Table 1.
Anti-viral activity and cytotoxicity of XMD7 compounds.
| Assay | Viral Strain | Compound | ED50a | CC50a |
|---|---|---|---|---|
| Viral Yield Reductionb | AD169 | XMD7-1 | 0.3 | – |
| AD169 | XMD7-2 | 0.3 | – | |
| AD169 | XMD7-27 | 0.4 | – | |
| Viral Yield Reductionb | Merlin (RCMV1111) | XMD7-1 | 2.5 | – |
| Merlin (RCMV1111) | XMD7-2 | 2.1 | ||
| Merlin (RCMV1111) | XMD7-27 | 2.4 | ||
| MTT Cytotoxicityc | – | XMD7-1 | – | >10 |
| – | XMD7-2 | – | >10 | |
| – | XMD7-27 | – | >10 |
a
μM.
b
Viral titre was assessed at 96 h post infection in the presence of each compound.
c
MTT assays were carried out after 96 h exposure of cells to each compound.